Search

everythinglearnresearchcommunity

for

Search:↓

User considers making Zix topical solution with ethanol/alcohol for hair loss treatment. Asks if crushing b6 and zinc into stemoxydine is possible.

The user experienced noticeable hairline regrowth after starting finasteride for crown hair loss, despite scalp irritation from topical minoxidil. They are impatient for crown results.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

A 30-year-old is using topical minoxidil 6% and finasteride for hair loss, showing significant progress over five months. They also use dermastamping, nizoral shampoo, and had a hair and scalp treatment.

The user experienced hair repigmentation and attributes improvements in hair and overall health to a carnivore diet, Boron, and Selenium supplementation. They stopped using finasteride after 20 years, noticed increased testosterone and libido, and observed hair regrowth with RU58841.

A 30-year-old man shared his positive experience with hair regrowth using Regenera Activ, topical Dutasteride, Minoxidil, and PRP over 12 weeks. He plans to continue with injectable Dutasteride and emphasizes the importance of starting treatment early to combat hair loss.

New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

User fought hair loss with Derminator microneedling, topical and oral minoxidil, and a 2000 FUE hair transplant. Derminator was a game changer, preventing further loss.

The conversation discusses hair loss treatments, including topical and oral minoxidil, finasteride, RU58841, and microneedling. Users suggest adding oral dutasteride or finasteride for more effective results.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.

A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.

The user has been using Minoxidil 5% since August and has noticed hair regrowth, with the left temple showing more concentrated growth and the right side having scattered single hairs. Some hairs are turning black, but the right side doesn't yet appear as full as the left.

The conversation discusses new hair loss treatments, mentioning Breezula and a promising treatment called pyrilutamide.

A male in his thirties with a Norwood 2 hairline questions if gym gains and supplements like creatine cause hair loss. Responses suggest that while exercise can slightly increase testosterone and DHT, genetics primarily determine hair loss, and treatments like finasteride are recommended for DHT control.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The user experienced hair regrowth and thickening using 1mg oral finasteride, 3mg oral minoxidil, biotin, vitamin D, red light therapy, and microneedling. Some shedding occurred around 4-6 weeks into the treatment.